Navigation Links
GlaxoSmithKline Responds to JAMA Articles
Date:9/11/2007

PHILADELPHIA, Sept. 11 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) believes that conclusions drawn from the most recent meta-analyses published by Drs. Nissen et. al. and Furberg et. al. in the Journal of the American Medical Association (JAMA) do not confirm a difference in the safety profile of Avandia(R) (rosiglitazone) and Actos(R) (pioglitazone). These analyses reflect limitations that are common to all meta-analyses, by the authors' own admission. These analyses do not yield data robust enough to guide doctors in selecting appropriate diabetes treatments for their patients. Comparisons between different meta-analyses with different endpoints and patient populations are even more unreliable.

The Actos meta-analysis is based on a small number of studies (19) provided directly by Takeda, and is heavily biased by data from the PROactive study (5,238 patients) which contributed 80 percent of the endpoint data. The patient population in the PROactive study was at high risk of cardiovascular disease.

-- PROactive compared diabetic patients on Actos to those on placebo.

Patients taking Actos to control blood sugar might be expected to have

fewer cardiovascular events than those who were not controlled on

medication, consistent with the primary results of PROactive (Hazard

Ratio 0.90 p=0.095). However, as described by FDA in the recent

Advisory Committee, at six months PROactive actually showed an

increased risk of heart attack (HR 1.2).

-- Applying the endpoint of CV death, myocardial infarction and stroke to

the data on Avandia across long-term clinical trials to enable a closer

like-for-like comparison with the Actos meta-analysis shows no

statistical difference between Avandia and comparators (a hazard ratio

of 1.03). In RECORD, a study specifically designed to look at

cardiovascular events, no real difference was seen between Avan
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. GlaxoSmithKline - Changes Lamictal(R) Label Appearance and Packaging
2. GlaxoSmithKline To Cultivate Non-Smoking Environment
3. GlaxoSmithKline to Supply United States with 8 Million flu vaccine, Fluarix
4. FDA Mislead On Asthma Drug By GlaxoSmithKline
5. GlaxoSmithKline Defends Its Products
6. GlaxoSmithKline launches diabetes and cancer drugs
7. Generic Products Compete With GlaxoSmithKline
8. GlaxoSmithKline Agrees To Settle Paxil Claims For $14 million
9. GlaxoSmithKlines Zofran Helps In Treatment Of Dehydration In Children
10. Ranbaxy Acquires Glaxosmithklines Generic Unit in Spain
11. GlaxoSmithKline’s Epilepsy Drug given the Green Signal by FD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... Doheny HealthDay Reporter , , TUESDAY, May 22 ... 2 diabetes with earlier development of precancerous colon lesions ... screenings at a younger age than others. "Based ... should get screenings earlier, possibly at age 40, rather ... clinical gastroenterology fellow at Washington University in St. Louis. ...
(Date:5/22/2012)... 2012) -- Up to half of all prostate cancer cells ... gene and formation of its unique protein -- but no ... Weill Cornell Medical College researchers have found that in these ... a little ball known as a chromatin, is warped in ... thousands of genes, turning them on or off to promote ...
(Date:5/22/2012)... (HealthDay News) -- The number of liver transplants in ... study finds. Researchers said one reason for the ... become more commonplace, and many of those livers end ... healthy enough to attempt a transplant. Another reason livers ... condition known as fatty liver disease, which is associated ...
(Date:5/22/2012)... enforcement of Law 42/2010, which extends the smoking ban ... the percentage of smokers (from 40.3% to 35.3%) and ... to men and women of all ages and occupations. ... study, carried out by the Society of Prevention of ... professionals) analysed the consumption of tobacco in the working ...
(Date:5/22/2012)... gene variants linked to prostate cancer may make ... according to a new study. On the other ... those symptoms, the study found. Researchers ... University in Chicago identified 38 genetic sequence variants ... healthy, white men enrolled in a prostate cancer ...
Breaking Medicine News(10 mins):Health News:Middle-Aged Diabetics May Need Earlier Colon Checks 2Health News:Middle-Aged Diabetics May Need Earlier Colon Checks 3Health News:Scientists unravel role of fusion gene in prostate cancer 2Health News:Scientists unravel role of fusion gene in prostate cancer 3Health News:Scientists unravel role of fusion gene in prostate cancer 4Health News:U.S. Liver Transplants Declining 2Health News:5 percent of workers gave up smoking when the anti-tobacco law took effect 2Health News:Study Ties Genes to Lower Urinary Tract Symptoms, Prostate Cancer Risk 2
... Inc.,(NYSE: SMA ), a leading independent provider of ... markets, announced today that,it will release third quarter financial ... market opens on Wednesday, November 12, 2008.,Symmetry Medical will ... Wednesday, November 12, 2008., A live Web cast ...
... and ... Milk Their Diets, HOUSTON, Oct. 30 The last decade ... seem to go in and out of,fashion like shoulder pads and hemlines. Yet, ... Texas residents --,remain overweight or obese., A new campaign crossing the country, ...
... for Sharing Product, Educational Expertise,with ASCs, ... Medical Inc. (B.,Braun) has launched a new ... and editorial information for ambulatory surgical centers,(ASCs)., ... The new online resource, http://www.asc.bbraunusa.com, ...
... RALEIGH, N.C., Oct. 30 TeleHealth Services, Inc., ... healthcare,market, has named Matthew K. Barker to the ... will include strategic market planning,market research and analysis., ... Mr. Barker,to direct its marketing efforts for its ...
... November 3, 2008, ALEXANDRIA, Va., Oct. 30 ... an amicus brief in support of a,courageous Vermont woman,s ... the amputation of her gangrenous arm caused by the ... the wholehearted backing of the Food and Drug,Administration (FDA), ...
... 30 Arno Therapeutics,Inc. (OTC Bulletin Board: ARNI.OB), ... announced the appointment,of William F. Hamilton, Ph.D. to ... audit committee. Dr. Hamilton has over 40 years ... particular expertise in the areas of,technology strategy and ...
Other Medicine News:Health News:Symmetry Medical to Report Third Quarter 2008 Financial Results on November 12, 2008 2Health News:Message to Houston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Houston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:B. Braun Medical Inc. Launches Ambulatory Surgical Center Website 2Health News:TeleHealth Names Matthew K. Barker to New Director of Marketing Position 2Health News:The Senior Citizens League's Comments on U.S. Supreme Court Case Wyeth v. Levine 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 3
(Date:5/22/2012)... -- Fox Insurance Company, a Medicare Part D provider with ... a judgment in the arbitration between the company and ... $3.3 million, following a suit against ProCare based on ... May 21, 2012, the U.S. District Court for the ... confirming the arbitration award after its May 7 th ...
(Date:5/22/2012)... -- Based on its recent analysis of the liquid ... with the 2012 North American Award for Product ... liquid handling technologies provide single improvements, no other ... by the Echo liquid handler. Setting ... platform enabling assay miniaturization due to the transfer ...
(Date:5/22/2012)... Conn., May 22, 2012   Valeritas , ... a new, simple disposable device for the delivery ... 2 diabetes, has selected dLife to ... number-one resource and community network for people living ... V-Go Life, a comprehensive diabetes lifestyle management and ...
Breaking Medicine Technology:Judge Upholds $3.3 Million Judgment In Favor of Fox Insurance Company Against Former Pharmacy Benefit Manager 2Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market 2Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market 3Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market 4Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market 5Valeritas Inc. Selects dLife's New Diabetes Patient Engagement Solution For Valeritas' V-go Disposable Insulin Delivery Device 2Valeritas Inc. Selects dLife's New Diabetes Patient Engagement Solution For Valeritas' V-go Disposable Insulin Delivery Device 3Valeritas Inc. Selects dLife's New Diabetes Patient Engagement Solution For Valeritas' V-go Disposable Insulin Delivery Device 4New Research Holds Promise for Gene Engineering and Therapy 19039 1New Research Holds Promise for Gene Engineering and Therapy 19039 2New Research Holds Promise for Gene Engineering and Therapy 19039 3New Research Holds Promise for Gene Engineering and Therapy 19039 4Reportlinker Adds Personalized Medicine Scientific 26amp 3B Commercial Aspects 16018 1Reportlinker Adds Personalized Medicine Scientific 26amp 3B Commercial Aspects 16018 2Reportlinker Adds Personalized Medicine Scientific 26amp 3B Commercial Aspects 16018 3Reportlinker Adds Personalized Medicine Scientific 26amp 3B Commercial Aspects 16018 4Babies born earlier in areas near busy road junctions 80690 1Babies born earlier in areas near busy road junctions 80690 2
... its active ... metabolites, ... that the United States Patent and Trademark Office,has issued a Notice ... Analogues," covering,the composition of matter of a family of molecules invented ...
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), ... and commercialization of novel drugs in the,therapeutic ... today,announced that the Journal of Antimicrobial Chemotherapy ... Isolates of the USA300 clone of MRSA,to ...
Other Medicine Technology:Pharmasset Receives Notice of Allowance 2Pharmasset Receives Notice of Allowance 3Pharmasset Receives Notice of Allowance 4Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA) 2Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA) 3Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA) 4Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA) 5
Straight shafts with pointed 4.5 mm tying surfaces. Scalloped wide handle with dull finish....
Colibri style shafts with delicate pointed 1 mm tips. Open serrated handle with dull finish....
Straight shafts with 0.12 mm teeth and 5 mm tying platform. Serrated handle with polished finish. Most popular size or model....
Straight shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Medicine Products: